CD4+ T cells specific for gp350 (and other virion glycoproteins) are capable of recognising B cells at very early time-points post-EBV infection in vitro ([17] and Figs 7 and 8) and may well contribute towards vaccine-induced protection. Here, CD4 is linked to Epstein-Barr virus infection.